XML 43 R26.htm IDEA: XBRL DOCUMENT
v3.24.1

Commitments and Contingencies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract] |
Schedule of Contractual Clinical Trials | The following is a summary of the contractual clinical trials discussed below as of December 31, 2023: Schedule of Contractual Clinical Trials
Description of Clinical Trial |  | Type of Clinical Trial |  | Institution |  | Estimated Start Date |  | Estimated End Date |  | Number of Patients in Trial |  | Study Objective |  | Clinical Update |  | NCT No. |  |  | Remaining Financial Contractual Commitment |
LB-100 combined with carboplatin, etoposide and atezolizumab in small cell lung cancer |  | Phase 1b |  | City of Hope and Sarah Cannon |  | March 2021 |  | March 2026 |  | 14 to 36 |  | Determine RP2D |  | Three patients entered |  | NCT04560972 |  | $ | 2,433,000 |
LB-100 combined with doxorubicin in sarcoma |  | Phase 1b |  | GEIS |  | June 2023 |  | June 2024 |  | 9 to 18 |  | Determine MTD and RP2D |  | One patient entered |  | NCT05809830 |  |  | 3,580,000 |
LB-100 in high grade gliomas |  | Phase 0 pharmacology study |  | National Cancer Institute |  | January 2019 |  | August 2022 |  | 7 |  | Determine the penetration of LB-100 into high grade gliomas after IV injection |  | Closed. No or minimal penetration of LB-100 into high grade gliomas after IV injection |  | NCT03027388 |  |  |  | (2)
Doxorubicin with or without LB-100 in sarcoma |  | Randomized Phase 2 |  | GEIS |  | July 2024 |  | June 2026 |  | 150 |  | Determine efficacy: PFS |  | Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical trial) |  | NCT05809830 |  |  |  | (1)
LB-100 combined with dostarlimab in ovarian clear cell carcinoma |  | Phase 1b/2 |  | MD Anderson |  | March 2024 |  | December 2025 |  | 21 |  | Determine the survival of patients with ovarian clear cell carcinoma |  | No patients entered at December 31, 2023 |  | NCT06065462 |  |  |  | (2)
Total |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 6,013,000 |
| (1) | The financial contractual commitment of the GEIS Randomized Phase 2 clinical trial is included in the financial contractual commitment of the GEIS Phase 1b trial. .
| (2) | There is no remaining financial contractual commitment associated with this clinical trial.

X
- Definition Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (S-X 210.12-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration